Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation

Cooling, L.L.W.; Sherbeck, J.; Mowers, J.C.; Hugan, S.L.

doi:10.21307/immunohematology-2019-004

.blurhash-client-img { display: none !important; }

Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation

Immunohematology

Volume 33 (2017): Issue 1 (March 2017)

By: L.L.W. Cooling, J. Sherbeck, J.C. Mowers and S.L. Hugan

Paid access

|Oct 2019

Authors

L.L.W. Cooling

lcooling@med.umich.edu

Transfusion Medicine, University of Michigan Hospitals, Department of Pathology, 2F225 UH-Blood Bank, Ann Arbor, MI, United States

J. Sherbeck

Pathology House Officer IV, University of Michigan, Department of Pathology, Ann Arbo, United States

J.C. Mowers

Pathology House Officer III, University of Michigan, Department of Pathology, Ann Arbo, United States

S.L. Hugan

Immunohematology Reference Laboratory, University of Michigan Hospitals, Ann Arbor, MI, United States

DOI: https://doi.org/10.21307/immunohematology-2019-004 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X

Journal RSS Feed

Language: English

Page range: 15 - 21

Published on: Oct 9, 2019

Published by: American National Red Cross

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

checkpoint inhibitor,

anemia,

Related subjects:

© 2019 L.L.W. Cooling, J. Sherbeck, J.C. Mowers, S.L. Hugan, published by American National Red Cross
This work is licensed under the Creative Commons License.

Previous article Volume 33 (2017): Issue 1 (March 2017)Next article